The company joins a wave of global pharma companies reshoring operations to strengthen the US supply chain and meet patient ...

Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires.

Concerns about bribery allegations, angry CBS News staff and a looming high-stakes merger made for tense monthslong negotiations. The travel-review company's shares have fallen after it rejected ...

The reinstatement of two soccer bribery convictions, President Trump's asylum ban being blocked, FDA's approval of ...

A federal bankruptcy court this week approved the sale of 23andMe to TTAM Research Institute - a new company launched by ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

Stocks in the healthcare industry fell ahead of June's nonfarm payrolls, which economists surveyed by The Wall Street Journal expect to show declining job creation. Centene stock plummeted 40% after ...

According to Regeneron, the drug is a bispecific antibody that binds to B-cell maturation antigen (BCMA) on cancerous plasma cells and CD3 on T cells, directing the immune system to attack and destroy ...